OncoMatch/Clinical Trials/NCT02391051
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
Is NCT02391051 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT2A, CN0, CM0 (clinical TNM)
Grade: Gleason Score ≤ 6 (3+3) (Gleason)
Tumor stage: cT1-2a cN0 cM0; Tumor stage ≥ T2b [excluded]; Known metastasis: N+ and/or M1 [excluded]; Gleason Score of index lesion ≤ 6 (3+3)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify